Immunologic approaches to antigen discovery for cancer vaccines

Bibliography

• COLEY WB: The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. (1893) 105:487–511.
   Google Scholar
• BENDANI M, GOCKE CD, KOBRIN CB et al: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. (1999) 5:1171–1177.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the clinical relevance of therapeuticvaccines for cancer.
   Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Merl. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• ••See reference 2 for annotation.
   Google Scholar
• ROSENBERG SA, YANG JC, SCHVVARTZENTRUBER DL et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Merl. (1998) 4:321–327.
   PubMed Web of Science ®Google Scholar
• ••See reference 2 for annotation.
   Google Scholar
• SALGALLER ML, TJOA BA, LODGE PA et al: Dendritic cell-based immunotherapy of prostate cancer. Grit. Rev. Immunol. (1998) 18:109–119.
   PubMed Web of Science ®Google Scholar
• ••See reference 2 for annotation.
   Google Scholar
• THEOBALD M, BIGGS J, DITTMER D, LEVINE AJ, SHERMAN LA: Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA (1995) 92:11993–11997.
   PubMed Web of Science ®Google Scholar
• WOLFEL T, HAUER M, SCHNEIDER J et al: A p161NK4a-insensitive CDK4 mutant targeted by cytotolytic T lymphocytes in a human melanoma. Science (1995) 269:1281–1284.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, EL-GAMIL M, LI YF et al.: A mutatedB-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. (1996) 183:1185–1192.
   PubMed Web of Science ®Google Scholar
• COULIE PG, LEHMANN F, LETHE B et al: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA (1995) 92:7976–7980.
   PubMed Web of Science ®Google Scholar
• FUCHS EJ, BEDI A, JONES RJ, HESS AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res. (1995) 55:463–466.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MJ, ESSERMAN L, BYARS NE ALLISON AC, LEVY R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol (1990) 145:1029–1036.
   Google Scholar
• CHEEVER MA, DISIS ML, BERNHARD et al: Immunity to oncogenic proteins. Immunol. Rev. (1995) 145:33–59.
   PubMed Web of Science ®Google Scholar
• HODGE JW: Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol. Immunother. (1996) 43:127–134.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al: Identifi-cation of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA (1994) 91:6458–6462.
   PubMed Web of Science ®Google Scholar
• COX AL, SKIPPER J, C HEN Y et al.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 264:716–719.
   Google Scholar
• ••First identification of tumour antigen using T-cells andbiochemical methods.
   Google Scholar
• BRICHARD V, VAN PEL A, WOLFER T et al.: The tyrosi-nase gene codes for an antigen recognized by autolo-gous cytotoxic T lymphocytes on HLA-A2 melanoma. J. Exp. Med (1993) 178:489–495.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al: Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA (1994) 91:3515–3519.
   PubMed Web of Science ®Google Scholar
• COULIE PG, BRICHARD V, VAN PEL A et al: A new gene coding for adifferentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. (1994) 180:35–42.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• ••Identification of the first tumour-associated antigen usingcytotoxic T-cells.
   Google Scholar
• BOEL P, WILDMANN C, SENSI ML eta].: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 2:167–175.
   Google Scholar
• VAN DEN EYNDE B, PEETERS 0, DE BACKER 0 et al: A new family of gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. (1995) 182:689–698.
   PubMed Web of Science ®Google Scholar
• CHEN YT, SCANLAN M, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914–1918.
   PubMed Web of Science ®Google Scholar
• STOCKERT E, JAGER E, CHEN YT et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Merl. (1998) 187:1349–1354.
   PubMed Web of Science ®Google Scholar
• DIATCHENKO L, LAU Y F, CAMPBELL AP: Suppressionsubtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc. Natl. Acad. Sci. USA (1996) 93:6025–6030.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ROBBINS PF, WANG RF, ROSENBERG SA:Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer. Prin. Prac. Oncol (1996) 10:1–20.
   Google Scholar
• AMBINDER RF, LEMAS MV, MOORE S et al: Epstein-Barr virus and lymphoma. Cancer Treat. Res. (1999) 99:27–45.
   PubMedGoogle Scholar
• CHISARI FV, FERRARI C: Hepatitis B virus immuno-pathogenesis. Ann. Rev. Immunol (1995) 13:29–60.
   PubMed Web of Science ®Google Scholar
• BEAUDENON S, KREMSDORF D, CROISSANT 0 et al.: A novel type of human papillomavirus associated with genital neoplasias. Nature (1986) 321:246–249.
   Google Scholar
• TOES, RE, OSSENDORP, F, OFFRINGA, R, MELIEF, CJM:CD4 T cells and their role in antitumor immune responses. J. Exp. Med. (1999) 189:753–756.
   PubMed Web of Science ®Google Scholar
• BOOKMAN MA, SWERDLOW R, MATIS LA: Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J. Immunol. (1987) 139:3166–3170.
   PubMed Web of Science ®Google Scholar
• BOON T, CEROTTINI JC, VAN DEN EYNDE B et al.: Tumorantigens recognized by T lymphocytes. Ann. Rev. Immunol (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• RIMOLDI D, ROMERO P, CARREL S: The human melanoma antigen-encoding gene MAGE-1 is expressed by other tumor cells of neuroectodermal origin such as glioblastomas and neuroblastoma. Int. J. Cancer. (1993) 54:527–528.
   PubMed Web of Science ®Google Scholar
• BASSEUR F, MARCHAND M, VANWIJCK R et al.: Humangene MAGE-1, which codes for a tumor rejection antigen, is expressed by some breast tumors. Int. J. Cancer (1992) 52:839–841.
   PubMed Web of Science ®Google Scholar
• WANG RF, WANG X, ATWOOD AC, TOPALIAN SL, ROSENBERG SA: Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 284:1351–1354.
   PubMed Web of Science ®Google Scholar
• •Adaptation of genetic method used for identification of class I restricted tumour antigens to the class II system.
   Google Scholar
• WANG RF, WANG X, ROSENBERG SA: Identification of anovel MHC class ffrestricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J. Exp. Med. (1999) 189:1659–1667.
   PubMed Web of Science ®Google Scholar
• HUNT DF, HENDERSON, RA SHABANOWITZ J et al: Characterization of peptides bound to the class I MHC molecule HLA-A2 by mass spectrometry. Science (1992) 255:1261–1263.
   PubMed Web of Science ®Google Scholar
• CASTELLI C, STORKUS WJ, MAEURUR MJ et al.: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. (1995) 181:363–368.
   PubMed Web of Science ®Google Scholar
• HOGAN KT, EISINGER DP, CUPP SB 3rd et al.: The peptide recognized by HOA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lympho-cytes is derived from a mutated elongation factor 2 gene. Cancer Res. (1998) 58:5144–5150.
   Google Scholar
• BABCOCK B, ANDERSON BW, PAPAYANNOPOULOS I etal.: Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol. Immunol (1988) 35:1121–1233.
   Google Scholar
• HALDER T, PAWELEC G, KIRKIN AF et al: Isolation ofnovel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. (1997) 57:3238–3244.
   PubMed Web of Science ®Google Scholar
• PIEPER R, CHRISTIAN RE, GONZALES MI et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4+T cells. J. Exp. Med. (1999) 189:757–765.
   PubMed Web of Science ®Google Scholar
• VONDERHEITE RH, HAHN WC, SCHULTZE JL, NADLER LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10:673–679.
   PubMed Web of Science ®Google Scholar
• •Intellectual identification of a tumour antigen.
   Google Scholar
• SAHIN U, TURECI 0, SCHMITT H et al.: Human neoplasms elicit multiple immune responses in the autologous host. Proc. Natl. Acad. ScL USA (1995) 92:11810–11813.
   Google Scholar
• ••Initial use of SEREX for identification of tumour antigens.
   Google Scholar
• TRUECI 0, SAHIN U, PFREUNDSCHUH M: Serological analysis of human tumor antigens: molecular defini-tion and implications. Mol. Med. Today (1997) 3:342–349.
   PubMedGoogle Scholar
• OLD LJ, CHEN YT: New paths in human cancer serology. J. Exp. Med. (1998) 8:1163–1167.
   Google Scholar
• CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicularantigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. ScL USA (1997) 94:1914–1918.
   PubMed Web of Science ®Google Scholar
• WANG RF, JOHNSTON SL, ZENG G, TOPAPAIN SL, SCHWARTZENTRUBE DJ, ROSENBERG SA: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol (1998) 161:3598–3606.
   PubMedGoogle Scholar
• JAGER E, CHEN YT, DRIJTHOUT JW et al.: Simultaneoushumoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. (1998) 187:265–270.
   PubMed Web of Science ®Google Scholar
• •Demonstration of both T- and B-cell mediated immune responses to a TAA in a cancer patient.
   Google Scholar
• SCANLAN MJ, CHEN YT, WILLIAMSON AO et al: Charac-terization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer (1998) 76:652–658.
   PubMed Web of Science ®Google Scholar
• TURECI 0, SCHMITT, FADLE N, PFREUNDSCHUH M, SAHIN U: Molecular definition of a novel galectin which is immunogenic in patients with Hodkin's disease. J. Biol. Chem. (1997) 272:6416–6422.
   PubMed Web of Science ®Google Scholar
• GURE AO, ALTORKI NK, STOCKERT E, SCANLAN MJ, OLD LJ, CHEN YT: Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21. Cancer Res. (1998) 58:1034–1041.
   PubMed Web of Science ®Google Scholar
• GURE AO, TURECI 0, SAHIN U et al: SSX, a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer (1997) 72:964–971.
   Google Scholar
• RIKER A, CORMIER J, PANELLI M et al.: Immune selectionafter antigen-specific immunotherapy of melanoma. Surgery (1999) 126:112–120.
   PubMed Web of Science ®Google Scholar
• LEE PP, YEE C, SAVAGE PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. (1998) 5:677–684.
   Web of Science ®Google Scholar
• AARNDOUSE CA, VAN DEN DOEL PB, HEEMSKERK B, SCHRIER PI: Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer (1999) 82:442–448
   PubMed Web of Science ®Google Scholar
• MANDRUZZATO S, BRASSEUR F, ANDRY G, BOON T, VAN DER BRUGGEN P: A CASP-8 mutation recognized by sytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. (1997) 186:785–793.
   PubMed Web of Science ®Google Scholar
• GAUDIN C, KREMER F, ANGEVIN E, SCOTT V, TRIEBEL F: A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J. Immunol (1999) 162:1730–1739.
   PubMed Web of Science ®Google Scholar
• YANG D, NAKAO M, SHICHIJO S et al: Identification a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. (1999) 59:4056–4063.
   PubMed Web of Science ®Google Scholar
• GUEGAUN M, PATARD JJ, GAUGLER B et al.: An antigen recognized byautologous CTLs on a human bladder carcinoma. J. Immunol (1998) 160:6188–6194.
   PubMed Web of Science ®Google Scholar
• CHIARI R, FOURY F, DE PLAEN E, BAURAIN JF, THONNARD J, COULIE PG: Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. (1999) 59:5785–5792.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, EL-GAMIL M, LI Y et al.: Cloning of a newgene encoding anantigen recognized by melanoma- specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol. (1995) 154:5944–5950.
   PubMed Web of Science ®Google Scholar
• IKEDA H, LETHE B, LEHMANN F et al: Characterization of antigen that isrecognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 6:199–208.
   PubMed Web of Science ®Google Scholar
• GAUGLER B, BROUWENSTIJN N, VANTOMME V et al.: A new gene coding for an antigen recognized by autolo-gous cytolytic T lymphocytes on a human renal cell carcinoma. Immunogenetics (1996) 44:232–330.
   Google Scholar
• SHICHIJO S, NAKAO M, IMAI Y et al.: A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. (1998) 187:277–288.
   PubMed Web of Science ®Google Scholar
• WANG RF, ROBBINS PF, KAWAKAMI Y, KANG XQ, ROSENBERG SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. (1995) 181:799–804.
   PubMed Web of Science ®Google Scholar
• WANG RF, APPELLA E, KAWAKAMI Y, KANG X, ROSENBERG SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. (1996) 184:2207–2216.
   PubMed Web of Science ®Google Scholar